Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase

Martin Begemann, Sharafadeen A. Kashimawo, Ruth M. Lunn, Thomas Delohery, Yu Jeong A. Choi, Susan Kim, Daniel F. Heitjan, Regina M. Santella, Peter B. Schiff, Jeffrey N. Bruce, I. Bernard Weinstein

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Protein kinase C (PKC) is a central component in signal transduction and growth control and might be an appropriate target for the chemotherapy of human brain tumors. This study demonstrates that the staurosporine derivative Ro 31-8220, a potent PKC inhibitor, inhibited the growth of 7 human brain tumor cell lines with an IC50 of about 2 μM. Calphostin C, a structurally unrelated PKC inhibitor, inhibited the growth of two of these cell lines with an IC50 of about 100 to 300 nM. Drug withdrawal and clonogenicity assays indicated that the growth inhibition by both of these compounds was irreversible. Morphologic studies, DNA fragmentation studies and flow cytometric assays showed that the treated glioblastoma cells underwent apoptosis. Treatment of glioblastoma cells with Ro 31-8220 lend to a rapid decline in the level of the anti-apoptosis protein bcl-2. At least three of the glioblastoma cell lines carried mutant p53 alleles with missense mutations in the DNA binding domain of p53. Therefore, the induction of apoptosis in these cell lines occurred through a p53-independent mechanism. Furthermore treatment of these glioblastoma cell lines with Ro 31-8220 or calphostin C led to an increase of cells in the G2-M phase of the cell cycle. This correlated with a decrease in CDC2-associated histone H1 kinase activity as well as a decrease in the level of the CDC2 protein as shown by immunoblotting. When added to subcellullar assays Ro 31-8220 markedly inhibited CDC2 histone H1 kinase activity with an IC50 of 100 nM, but calphostin C directly inhibited this kinase activity only at very high concentrations (above 100 μM). Thus these compounds inhibit the growth of glioblastoma cells through novel mechanisms. Ro 31-8220, in particular, might be a useful agent for the treatment of human brain tumors.

Original languageEnglish (US)
Pages (from-to)3139-3152
Number of pages14
JournalAnticancer Research
Volume18
Issue number5 A
StatePublished - Sep 1 1998

Fingerprint

Glioblastoma
Phosphotransferases
Apoptosis
Cell Line
Brain Neoplasms
Protein Kinase C
Inhibitory Concentration 50
Growth
Protein C Inhibitor
Protein Kinase Inhibitors
Staurosporine
G2 Phase
DNA Fragmentation
Missense Mutation
Tumor Cell Line
Immunoblotting
Cell Division
Signal Transduction
Cell Cycle
Proteins

Keywords

  • Bcl-2
  • Chemotherapy
  • p53
  • PKC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Begemann, M., Kashimawo, S. A., Lunn, R. M., Delohery, T., Choi, Y. J. A., Kim, S., ... Weinstein, I. B. (1998). Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Anticancer Research, 18(5 A), 3139-3152.

Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. / Begemann, Martin; Kashimawo, Sharafadeen A.; Lunn, Ruth M.; Delohery, Thomas; Choi, Yu Jeong A.; Kim, Susan; Heitjan, Daniel F.; Santella, Regina M.; Schiff, Peter B.; Bruce, Jeffrey N.; Weinstein, I. Bernard.

In: Anticancer Research, Vol. 18, No. 5 A, 01.09.1998, p. 3139-3152.

Research output: Contribution to journalArticle

Begemann, M, Kashimawo, SA, Lunn, RM, Delohery, T, Choi, YJA, Kim, S, Heitjan, DF, Santella, RM, Schiff, PB, Bruce, JN & Weinstein, IB 1998, 'Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase', Anticancer Research, vol. 18, no. 5 A, pp. 3139-3152.
Begemann, Martin ; Kashimawo, Sharafadeen A. ; Lunn, Ruth M. ; Delohery, Thomas ; Choi, Yu Jeong A. ; Kim, Susan ; Heitjan, Daniel F. ; Santella, Regina M. ; Schiff, Peter B. ; Bruce, Jeffrey N. ; Weinstein, I. Bernard. / Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. In: Anticancer Research. 1998 ; Vol. 18, No. 5 A. pp. 3139-3152.
@article{33b6b76d74c2487bb141ad2df6e105da,
title = "Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase",
abstract = "Protein kinase C (PKC) is a central component in signal transduction and growth control and might be an appropriate target for the chemotherapy of human brain tumors. This study demonstrates that the staurosporine derivative Ro 31-8220, a potent PKC inhibitor, inhibited the growth of 7 human brain tumor cell lines with an IC50 of about 2 μM. Calphostin C, a structurally unrelated PKC inhibitor, inhibited the growth of two of these cell lines with an IC50 of about 100 to 300 nM. Drug withdrawal and clonogenicity assays indicated that the growth inhibition by both of these compounds was irreversible. Morphologic studies, DNA fragmentation studies and flow cytometric assays showed that the treated glioblastoma cells underwent apoptosis. Treatment of glioblastoma cells with Ro 31-8220 lend to a rapid decline in the level of the anti-apoptosis protein bcl-2. At least three of the glioblastoma cell lines carried mutant p53 alleles with missense mutations in the DNA binding domain of p53. Therefore, the induction of apoptosis in these cell lines occurred through a p53-independent mechanism. Furthermore treatment of these glioblastoma cell lines with Ro 31-8220 or calphostin C led to an increase of cells in the G2-M phase of the cell cycle. This correlated with a decrease in CDC2-associated histone H1 kinase activity as well as a decrease in the level of the CDC2 protein as shown by immunoblotting. When added to subcellullar assays Ro 31-8220 markedly inhibited CDC2 histone H1 kinase activity with an IC50 of 100 nM, but calphostin C directly inhibited this kinase activity only at very high concentrations (above 100 μM). Thus these compounds inhibit the growth of glioblastoma cells through novel mechanisms. Ro 31-8220, in particular, might be a useful agent for the treatment of human brain tumors.",
keywords = "Bcl-2, Chemotherapy, p53, PKC",
author = "Martin Begemann and Kashimawo, {Sharafadeen A.} and Lunn, {Ruth M.} and Thomas Delohery and Choi, {Yu Jeong A.} and Susan Kim and Heitjan, {Daniel F.} and Santella, {Regina M.} and Schiff, {Peter B.} and Bruce, {Jeffrey N.} and Weinstein, {I. Bernard}",
year = "1998",
month = "9",
day = "1",
language = "English (US)",
volume = "18",
pages = "3139--3152",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase

AU - Begemann, Martin

AU - Kashimawo, Sharafadeen A.

AU - Lunn, Ruth M.

AU - Delohery, Thomas

AU - Choi, Yu Jeong A.

AU - Kim, Susan

AU - Heitjan, Daniel F.

AU - Santella, Regina M.

AU - Schiff, Peter B.

AU - Bruce, Jeffrey N.

AU - Weinstein, I. Bernard

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Protein kinase C (PKC) is a central component in signal transduction and growth control and might be an appropriate target for the chemotherapy of human brain tumors. This study demonstrates that the staurosporine derivative Ro 31-8220, a potent PKC inhibitor, inhibited the growth of 7 human brain tumor cell lines with an IC50 of about 2 μM. Calphostin C, a structurally unrelated PKC inhibitor, inhibited the growth of two of these cell lines with an IC50 of about 100 to 300 nM. Drug withdrawal and clonogenicity assays indicated that the growth inhibition by both of these compounds was irreversible. Morphologic studies, DNA fragmentation studies and flow cytometric assays showed that the treated glioblastoma cells underwent apoptosis. Treatment of glioblastoma cells with Ro 31-8220 lend to a rapid decline in the level of the anti-apoptosis protein bcl-2. At least three of the glioblastoma cell lines carried mutant p53 alleles with missense mutations in the DNA binding domain of p53. Therefore, the induction of apoptosis in these cell lines occurred through a p53-independent mechanism. Furthermore treatment of these glioblastoma cell lines with Ro 31-8220 or calphostin C led to an increase of cells in the G2-M phase of the cell cycle. This correlated with a decrease in CDC2-associated histone H1 kinase activity as well as a decrease in the level of the CDC2 protein as shown by immunoblotting. When added to subcellullar assays Ro 31-8220 markedly inhibited CDC2 histone H1 kinase activity with an IC50 of 100 nM, but calphostin C directly inhibited this kinase activity only at very high concentrations (above 100 μM). Thus these compounds inhibit the growth of glioblastoma cells through novel mechanisms. Ro 31-8220, in particular, might be a useful agent for the treatment of human brain tumors.

AB - Protein kinase C (PKC) is a central component in signal transduction and growth control and might be an appropriate target for the chemotherapy of human brain tumors. This study demonstrates that the staurosporine derivative Ro 31-8220, a potent PKC inhibitor, inhibited the growth of 7 human brain tumor cell lines with an IC50 of about 2 μM. Calphostin C, a structurally unrelated PKC inhibitor, inhibited the growth of two of these cell lines with an IC50 of about 100 to 300 nM. Drug withdrawal and clonogenicity assays indicated that the growth inhibition by both of these compounds was irreversible. Morphologic studies, DNA fragmentation studies and flow cytometric assays showed that the treated glioblastoma cells underwent apoptosis. Treatment of glioblastoma cells with Ro 31-8220 lend to a rapid decline in the level of the anti-apoptosis protein bcl-2. At least three of the glioblastoma cell lines carried mutant p53 alleles with missense mutations in the DNA binding domain of p53. Therefore, the induction of apoptosis in these cell lines occurred through a p53-independent mechanism. Furthermore treatment of these glioblastoma cell lines with Ro 31-8220 or calphostin C led to an increase of cells in the G2-M phase of the cell cycle. This correlated with a decrease in CDC2-associated histone H1 kinase activity as well as a decrease in the level of the CDC2 protein as shown by immunoblotting. When added to subcellullar assays Ro 31-8220 markedly inhibited CDC2 histone H1 kinase activity with an IC50 of 100 nM, but calphostin C directly inhibited this kinase activity only at very high concentrations (above 100 μM). Thus these compounds inhibit the growth of glioblastoma cells through novel mechanisms. Ro 31-8220, in particular, might be a useful agent for the treatment of human brain tumors.

KW - Bcl-2

KW - Chemotherapy

KW - p53

KW - PKC

UR - http://www.scopus.com/inward/record.url?scp=0031762618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031762618&partnerID=8YFLogxK

M3 - Article

C2 - 9858877

AN - SCOPUS:0031762618

VL - 18

SP - 3139

EP - 3152

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -